Fate Therapeutics Inc
FATE0.956USD
-0.007-0.76%
收盤 09/15, 16:00（美東）報價延遲15分鐘
109.59M總市值
虧損本益比TTM
關於 Fate Therapeutics Inc 公司
Fate Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司致力於爲癌症和自身免疫性疾病患者提供一系列誘導性多能幹細胞 (iPSC) 衍生的細胞免疫療法。其專有的誘導性多能幹細胞 (iPSC) 產品平臺將人類 iPSC 的多重工程與單細胞選擇相結合，以創建克隆主 iPSC 系。該公司的平臺旨在克服使用患者或供體來源的細胞製造細胞療法的衆多限制。利用其專有的 iPSC 產品平臺，該公司正在推進現成的、多重工程化的自然殺傷 (NK) 細胞和 T 細胞候選產品，這些產品經過選擇性設計，結合了對細胞功能的新型合成控制。其 iPSC 衍生的、嵌合抗原受體 (CAR) 靶向的 NK 細胞和 T 細胞候選產品包括 FT819、FT522、FT576、FT825、FT819、FT522 等。
公司簡介
公司代碼FATE
公司名稱Fate Therapeutics Inc
上市日期Oct 01, 2013
CEODr. Bahram Valamehr, Ph.D.
員工數量181
證券類型Ordinary Share
年結日Oct 01
公司地址12278 Scripps Summit Drive
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編92131
電話18588751803
網址https://fatetherapeutics.com/
公司代碼FATE
上市日期Oct 01, 2013
CEODr. Bahram Valamehr, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.61K
-18.06%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
58.39K
-13.40%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Dr. Karin Jooss, Ph.D.
Dr. Karin Jooss, Ph.D.
Independent Director
Independent Director
9.85K
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.61K
-18.06%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
58.39K
-13.40%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Redmile Group, LLC
11.17%
ARK Investment Management LLC
8.94%
The Vanguard Group, Inc.
7.60%
BlackRock Institutional Trust Company, N.A.
7.47%
Citadel Advisors LLC
3.94%
其他
60.88%
持股股東
持股股東
佔比
Redmile Group, LLC
11.17%
ARK Investment Management LLC
8.94%
The Vanguard Group, Inc.
7.60%
BlackRock Institutional Trust Company, N.A.
7.47%
Citadel Advisors LLC
3.94%
其他
60.88%
股東類型
持股股東
佔比
Investment Advisor
29.67%
Investment Advisor/Hedge Fund
27.56%
Hedge Fund
11.10%
Research Firm
6.68%
Venture Capital
3.30%
Individual Investor
1.71%
Pension Fund
0.15%
Bank and Trust
0.11%
Family Office
0.10%
其他
19.62%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
418
107.82M
94.06%
-31.88M
2025Q1
445
110.00M
95.96%
-29.05M
2024Q4
487
105.43M
92.56%
-50.79M
2024Q3
521
119.20M
104.73%
-42.15M
2024Q2
531
125.64M
110.45%
-29.93M
2024Q1
543
126.44M
111.19%
-6.65M
2023Q4
556
99.29M
100.70%
-34.38M
2023Q3
581
100.01M
101.45%
-44.66M
2023Q2
611
113.36M
115.11%
-33.43M
2023Q1
624
117.20M
119.39%
-6.61M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Redmile Group, LLC
12.87M
11.23%
--
--
Mar 31, 2025
ARK Investment Management LLC
10.31M
9%
+10.31M
--
Mar 31, 2025
The Vanguard Group, Inc.
10.31M
8.99%
-22.58K
-0.22%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.39M
7.32%
-99.57K
-1.17%
Mar 31, 2025
Citadel Advisors LLC
4.29M
3.74%
-93.10K
-2.12%
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
3.38M
2.95%
--
--
Mar 31, 2025
Vestal Point Capital, LP
2.52M
2.19%
+50.85K
+2.06%
Mar 31, 2025
Baker Bros. Advisors LP
3.26M
2.84%
--
--
Mar 31, 2025
Acadian Asset Management LLC
2.47M
2.16%
+999.77K
+67.84%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.59M
2.26%
-306.82K
-10.59%
Mar 31, 2025
查看更多
持股ETF
更新時間: 9月2日 週二
更新時間: 9月2日 週二
機構名稱
佔比
WisdomTree BioRevolution Fund
0.61%
Invesco NASDAQ Future Gen 200 ETF
0.41%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Broad Market ETF
0%
iShares Genomics Immunology and Healthcare ETF
0%
查看更多
WisdomTree BioRevolution Fund
佔比0.61%
Invesco NASDAQ Future Gen 200 ETF
佔比0.41%
iShares Micro-Cap ETF
佔比0.03%
iShares Russell 2000 Value ETF
佔比0.01%
ProShares Ultra Nasdaq Biotechnology
佔比0.01%
Invesco Nasdaq Biotechnology ETF
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
Schwab U.S. Broad Market ETF
佔比0%
iShares Genomics Immunology and Healthcare ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
